Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
February 2014—Thermo Fisher Scientific has signed an agreement with Cynvenio Biosystems, a molecular testing company focused on the genomic analysis of tumor biomarkers in the bloodstream, for rights to distribute its LiquidBiopsy platform. The automated LiquidBiopsy platform is designed to extract and isolate circulating tumor cells from a standard blood draw in preparation for high-content imaging and genomic analysis.
February 2014—Siemens Healthcare announced the launch of its drug-testing platform designed to meet the productivity, workflow, and workspace needs of mid-volume laboratories—the Viva-ProE System with EMIT technology. The system features a benchtop design with a compact footprint for smaller workspaces, has a capacity for 50 sample and 12 auxiliary positions, and can run up to 133 EMIT tests per hour.
February 2014—Aperiomics introduced its Absolute-NGS Pathogen Detection Platform, a package of three next-generation sequencing services for the identification of known and unknown pathogens, whether bacteria, virus, fungus, or parasite. From a single test, Aperiomics’ technology can simultaneously test for all pathogens using an unbiased sequencing and genomic analysis approach.
Bio-Rad Laboratories’ Geenius HIV-1/HIV-2 Supplemental Assay, which received premarket application approval from the FDA, can differentiate circulating antibodies to HIV types 1 and 2 in whole blood, serum, and plasma. The assay offers a three-step procedure that produces onscreen results in 30 minutes with full traceability.
Beckman Coulter Diagnostics has received FDA 510(k) clearance for the Access 25(OH) Vitamin D Total assay. The assay is available for use on the company’s Access 2 and UniCel DxI series of immunoassay systems and provides excellent stability and convenient storage through packaging designed to prevent light-induced reagent degradation.
February—Roche Diagnostics has signed a definitive purchase agreement with AvanSci Bio for all products associated with the high-performance microdissection of slide-mounted tissue sections. The system consists of instrumentation, software, and consumables used by researchers and clinicians to extract specific areas of tissue with high precision and purity for subsequent molecular analysis including real-time PCR, microarrays, and sequencing.
February 2014—Alpha-Tec Systems’ Stain Quality Control Slides are designed to ensure the quality, accuracy, and reliability of stain reagents and staining procedures. The slides provide a known positive and negative control that the laboratory can use to limit the batch-to-batch differences in staining procedures and standardize diagnostic criteria.
January 2015—eBioscience, an Affymetrix business that offers a broad spectrum of immunology and oncology research reagents, and the Binding Site Group have entered into a multiyear distribution agreement.
January 2015—Quest Diagnostics now offers BRCAvantage Plus, the company’s first suite of lab-developed test services for assessing genetic breast cancer risk based on clinically validated non-BRCA and BRCA genes.
January 2015—Enzo Life Sciences introduced an LH ELISA Kit for sensitive and rapid detection of luteinizing hormone.
